The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until now have declined to move forward with a more formal review. Two new studies have strengthened the link.
The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until now have declined to move forward with a more formal review. Two new studies have strengthened the link.